Avtor/Urednik		Kovač, Damjan; Lindič, Jelka; Kandus, Aljoša; Bren, Andrej F
Naslov		Alendronate prevents bone loss in kidney graft recipients
Tip		članek
Vir		In: Buturović-Ponikvar J, Bren AF, editors. Zbornik 2. slovenski nefrološki kongres z mednarodno udeležbo ob 30. letnici dialize in transplantacije ledvic v Sloveniji; 2000 sep 27-30; Brdo pri Kranju. Ljubljana: Klinični center, Klinični oddelek za nefrologijo,
Leto izdaje		2000
Obseg		str. 55-60
Jezik		eng
Abstrakt		Background. Loss of bone mineral density (BMD) most pronounced in the early posttransplant period, remains a serious problem after kidney transplantation. It seems reasonable to prevent bone loss in this early period rather than treat already manifested osteoporosis later after transplantation. Methods. We analysed two bone protecting treatments in two groups of patients with osteopenia and osteoporosis in the early post-transplant period. Group A (N=6; two men, four women-two postmenopausal) was treated with alendronate 10 mg/d, calcium carbonate 2 g/d and calcitriol 0.25mg/d, group B (N=6; three men, three women-one postmenopausal) was treated with calcium carbonate 2 g/d and calcitriol 0.25mg/d. All patients were treated with cyclosporine, methylprednisolone and first two weeks after transplantation with azathyoprine. At introduction of bone protecting treatment all patients had normal serum calcium, serum creatinine below 200 micro mol/L and intact PTH above 50 ng/L none of the patients had previous parathyroideclomy. Bone protecting treatment was introduced 20 +- 9 days after transplanlation. BMD was measured by dual energy x-ray absorptiometry at the lumbar spine within three weeks after transplantation and atter six months of treatment. Results. BMU of the lumbar spine after six months of treatment increased by 6.4% (from 0.802 +- 0.079 g/cm2 to 0.858 +- 0.075 g/cm2) (N=6, P<0.05) in group A and decreased by 9,3% (from 0.861 +- 0,086 g/cm2 to 0,781 +- 0,094 g/cm2) (N=6, P<0.05) in group B. Intact PTH decreased from 215 +- 102 ng/L to 98 +- 41 ng/L in group A and from 332 +- 397 ng/L to 63 +- 23 ng/L in group B during 6 months of treatment. Serum calcium, phosphate, creatinine, activiry of total alkaline phosphatase did not change significantly during treatment. No side effects of alendronate were observed. Conclusions. (Abstract truncated at 2000 characters)
Deskriptorji		KIDNEY TRANSPLANTATION ALENDRONATE OSTEOPOROSIS CYCLOSPORINE METHYLPREDNISOLONE AZATHIOPRINE BONE DENSITY SPINE CALCIUM PHOSPHATES CREATININE ALKALINE PHOSPHATASE